Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Restructuring Costs (2020 - 2025)

BioNexus Gene Lab's Restructuring Costs history spans 6 years, with the latest figure at $181095.0 for Q4 2025.

  • Quarterly results put Restructuring Costs at $181095.0 for Q4 2025, up 9.14% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (down 16.23% YoY), and the annual figure for FY2025 was $1.5 million, down 16.23%.
  • Restructuring Costs for Q4 2025 was $181095.0 at BioNexus Gene Lab, down from $445691.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $3.1 million in Q3 2023 to a low of -$2.0 million in Q4 2023.
  • The 5-year median for Restructuring Costs is $426404.5 (2021), against an average of $440918.4.
  • The sharpest move saw Restructuring Costs surged 1972.81% in 2021, then plummeted 506.52% in 2023.
  • Year by year, Restructuring Costs stood at $433985.0 in 2021, then grew by 12.41% to $487858.0 in 2022, then plummeted by 506.52% to -$2.0 million in 2023, then skyrocketed by 108.37% to $165932.0 in 2024, then increased by 9.14% to $181095.0 in 2025.
  • According to Business Quant data, Restructuring Costs over the past three periods came in at $181095.0, $445691.0, and $516790.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.